Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Evotec and Bristol Myers Squibb have announced progress in their strategic protein degradation partnership.

Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs utilizing the PEDAL platform.

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.

The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.

Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.

27 drugs within Medicare will face penalties for having their prices raised faster than the rate of inflation.

The impact of the potential ban would have serious consequences for the availability of many drugs for European patients.

FDA has approved Acadia Pharmaceuticlas’ Daybue (trofinetide), the first treatment for Rett syndrome, a rare genetic disorder.

FDA has approved Pfizer’s ZAVZPRET (zavegepant), a new nasal spray treatment for migraine.

FDA is seeking $7.2 billion to enhance food safety and advance medical product availability.

Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.

Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.

Even after an FDA advisory panel voted 14–1 in October 2022 to remove the drug, Makena manufacturer Covis Pharma continued to press for some continued access to the therapy.

Catalent is expanding its UpTempo AAV platform to accelerate the development of gene therapies.

Vetter has become a participant of the UN Global Compact Network.

Congressional leaders are investigating how pharmacy benefit managers determine health plan coverage and charges for medicines.

Actylis new 30,000-ft² API manufacturing facility is located in Eugene, Ore.

Sotatercept, a drug candidate acquired by Merck in an $11.5 billion acquisition, showed statistically significant improvements in various measures.

Janssen has received a positive opinion from EMA for AKEEGA plus prednisone or prednisolone for the treatment of BRCA1/2 gene-mutated metastatic castration resistant prostate cancer.

Any patients who have received the identified lots or have any questions regarding the recall should contact their pharmacy or immediately contact a health provider in terms of medical advice.

The guidance is intended to build on the existing International Council for Harmonisation (ICH) quality guidance.

The new guidance provides detailed recommendations to drug developers with a target of helping to ensure that drug developers provide adequate information to assess potency at each stage of a product’s life cycle.

EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.

PAT is crucial to process control and real-time release in continuous manufacturing of solid-dosage drugs.

Technological advances will help ease pressure on pharma supply chains, allowing for greater visibility and less uncertainty.

Lilly will cap insulin prices for patients with and without insurance at $35 per month.